Andrew Witty

Andrew Philip Witty currently works at GlaxoSmithKline, Inc., as Chief Executive Officer, Pharmaceutical Research & Manufacturers of America, as Director, The University of Nottingham, as Chancellor from 2013, and Business Council for Britain, as Member.
Sir Witty also formerly worked at Genelabs Technologies, Inc., as Chief Executive Officer from 2009 to 2011, GSK Plc, as Chief Executive Officer & Executive Director from 2008 to 2017, InGensa, Inc., as Chief Executive Officer, GlaxoSmithKline Australia Pty Ltd., as Chief Executive Officer & Director, Optum, Inc., as Chief Executive Officer from 2018 to 2021, UnitedHealth Group, Inc., as Chief Executive Officer & Director from 2021 to 2025, Synthego Corp., as Director, Biocompatibles International Ltd., as Director-Business Development, United Kingdom Department for Business, Innovation & Skills, as Lead Non-Executive Director, INSEAD, as Director in 2012, Glaxo Holdings Plc, as Director-Pharmacy & Distribution, GlaxoSmithKline South Africa (Pty) Ltd., as Managing Director, Singapore Land Authority, as Director, Glaxo Wellcome South Africa Pty Ltd., as Area Director, G1 Therapeutics, Inc., as Independent Director from 2017 to 2020, Oxford Nanoimaging Ltd., as Director from 2017 to 2018, Singapore Economic Development Board, as Member-International Advisory Council, European Federation of Pharmaceutical Industries & Assns, as President from 2010 to 2013, Glaxo Wellcome, Inc., as Vice President & General Manager-Marketing, and GlaxoSmithKline Pte Ltd., as Senior Vice President-Asia Pacific.
Sir Witty received his undergraduate degree from The University of Nottingham.